comparemela.com

Latest Breaking News On - Pharmaceutical inc - Page 7 : comparemela.com

Clearbridge Investments LLC Sells 469,676 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Clearbridge Investments LLC Sells 469,676 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesWells fargo companyDimensional fund advisorsClearbridge investmentsMorgan stanleyCantor fitzgeraldUs bancorpUltragenyx pharmaceutical incMetlife investment managementExchange commissionRaymond james associatesUltragenyx pharmaceuticalFree reportMontreal canLife investment managementFund advisors

Collegium Pharmaceutical Inc Reports Record Earnings for Q4 and Full-Year 2023

Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reaffirmed at Cantor Fitzgerald

Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reaffirmed at Cantor Fitzgerald
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesPiper sandlerRobertw bairdUs bancorpMorgan stanleyWells fargo companyLazard asset managementUltragenyx pharmaceutical incCantor fitzgeraldUltragenyx pharmaceutical company profileComerica bankUltragenyx pharmaceuticalFree reportModerate buyGet free reportAsset management

Ultragenyx Pharmaceutical Inc Q4 Loss decreases, beats estimates

Ultragenyx Pharmaceutical Inc (RARE) revealed Loss for fourth quarter that decreased from the same period last year and beat the Street estimates. The company's earnings came in at -$123.

Ultragenyx pharmaceutical incThomson reutersPharmaceutical incAnalyst estimatesWall streetOrporate resultsUsiness newsUltragenyx pharmaceutical inc

PRIMECAP Management Bolsters Stake in Biomarin Pharmaceutical Inc

On the last day of 2023, PRIMECAP Management (Trades, Portfolio) made a notable addition to its investment portfolio by acquiring additional shares in Biomarin Pharmaceutical Inc (NASDAQ:BMRN). This move increased PRIMECAP Management (Trades, Portfolio)'s total holdings in the company to 18,414,374 shares, solidifying its position with a 1.5% portfolio weight and a 9.78% stake in Biomarin Pharmaceutical.

United statesJefferies groupBiomarin pharmaceutical incFinancial health of biomarinAbout biomarin pharmaceuticalPharmaceutical incProfitability rankGrowth rankKen fisherJoel greenblattPrimecap managementBiomarin pharmaceuticalInvestment portfolioAmgen inc

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.